BZBogdan Zurawski
Bogdan Zurawski
*This is an algorithmically generated author record based on publicly available information.
Bogdan Zurawski has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- David P. Carbone
Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute, Columbus, Ohio, United States
2 shared publications - Luis Paz-Ares
Hospital Universitario 12 de Octubre
2 shared publications - Manuel Cobo
Department of Medical Oncology, Hospital Regional Universitario de Málaga, Málaga, Spain; IBIMA Plataforma BIONAND, Málaga, Spain
2 shared publications - Martin Reck
LungenClinic Grosshansdorf 18 Grosshansdorf
2 shared publications - Michael Schenker
Department of Oncology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
2 shared publications - Thomas John
Austin Hospital, Heidelberg, Australia
2 shared publications
Latest Publications
- Open Access
- 4 October 2024
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 20 (1) , 94-108
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
- 4 October 2024
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 20 (1) , 94-108
Open AccessLong-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
- Open Access
- 28 January 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 183, 174-187
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
- 28 January 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 183, 174-187
Open AccessFirst-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes